JP2023534951A5 - - Google Patents

Info

Publication number
JP2023534951A5
JP2023534951A5 JP2023502828A JP2023502828A JP2023534951A5 JP 2023534951 A5 JP2023534951 A5 JP 2023534951A5 JP 2023502828 A JP2023502828 A JP 2023502828A JP 2023502828 A JP2023502828 A JP 2023502828A JP 2023534951 A5 JP2023534951 A5 JP 2023534951A5
Authority
JP
Japan
Prior art keywords
dsrna
nucleotide
nucleotides
group
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534951A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041946 external-priority patent/WO2022016043A1/en
Publication of JP2023534951A publication Critical patent/JP2023534951A/ja
Publication of JP2023534951A5 publication Critical patent/JP2023534951A5/ja
Pending legal-status Critical Current

Links

JP2023502828A 2020-07-16 2021-07-16 組織特異的送達のためのコンジュゲートされたオリゴヌクレオチド Pending JP2023534951A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052811P 2020-07-16 2020-07-16
US63/052,811 2020-07-16
PCT/US2021/041946 WO2022016043A1 (en) 2020-07-16 2021-07-16 Conjugated oligonucleotides for tissue specific delivery

Publications (2)

Publication Number Publication Date
JP2023534951A JP2023534951A (ja) 2023-08-15
JP2023534951A5 true JP2023534951A5 (enExample) 2024-07-25

Family

ID=79554340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023502828A Pending JP2023534951A (ja) 2020-07-16 2021-07-16 組織特異的送達のためのコンジュゲートされたオリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20220042015A1 (enExample)
EP (1) EP4181932A4 (enExample)
JP (1) JP2023534951A (enExample)
CN (1) CN116600817A (enExample)
AU (1) AU2021308657A1 (enExample)
CA (1) CA3174068A1 (enExample)
WO (1) WO2022016043A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033368A1 (en) * 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
US12366070B2 (en) 2021-04-23 2025-07-22 Stephen Cochran Cover for circular-profile downspouts having protection from animal/insect intrusion and damage/debris accumulation
US20240084301A1 (en) 2022-07-25 2024-03-14 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
WO2024040041A1 (en) * 2022-08-15 2024-02-22 Dicerna Pharmaceuticals, Inc. Regulation of activity of rnai molecules
WO2024069235A2 (en) 2022-09-30 2024-04-04 Sixfold Bioscience Ltd. Compositions containing oligonucleotides with theranostic applications
WO2025217569A1 (en) * 2024-04-11 2025-10-16 University Of Massachusetts Conjugated chemically-modified dsrna during ex vivo perfusion of organs
WO2025259747A2 (en) * 2024-06-12 2025-12-18 Alnylam Pharmaceuticals, Inc. Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745574B2 (en) * 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
CA3033368A1 (en) * 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
EP3517610A4 (en) * 2016-09-23 2020-05-27 National University Corporation Tokyo Medical and Dental University THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET
MX2020011570A (es) * 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
US20220228141A1 (en) * 2020-11-23 2022-07-21 University Of Massachusetts Oligonucleotides for dgat2 modulation

Similar Documents

Publication Publication Date Title
JP2023534951A5 (enExample)
JP2023550485A5 (enExample)
JP2023522701A5 (enExample)
JP2020536125A5 (enExample)
US8148344B2 (en) Compositions and methods for mediating RNAi in vivo
ES2537568T3 (es) Nuevos fármacos para inhibición de la expresión genética
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したoff−target効果を有するunaオリゴマー
JP2022515193A5 (enExample)
JP2023518268A5 (enExample)
JP6038017B2 (ja) 核酸を含む逆ミセル系及びその使用
JP2022528487A5 (enExample)
JP2023518439A5 (enExample)
JP7197463B2 (ja) Smn2の調節のための化合物及び方法
JP2011517676A5 (enExample)
WO2023022229A1 (ja) モルホリノ核酸を含む修飾ヘテロ核酸
JP7560616B2 (ja) 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法
JP2023544413A5 (enExample)
JP2022188237A (ja) 転写プロセシングの調節のための化合物及び方法
EP3516062A1 (en) Myostatin irna compositions and methods of use thereof
JP2024522068A5 (enExample)
JP2024528701A5 (enExample)
JP2024509783A5 (enExample)
JP2023530072A (ja) Pmp22を調節するための化合物及び方法
JP2026506091A (ja) ハンチンチン発現を調節するための対立遺伝子選択的化合物及び方法
WO2024173762A2 (en) Compounds and methods for reducing app expression